262 results on '"Valent A"'
Search Results
2. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
3. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
4. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
5. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML
6. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
7. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
8. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
10. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
11. Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features
12. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
13. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
14. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
15. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
16. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
17. Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
18. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study
19. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
20. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
21. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
22. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
23. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS
24. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
25. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML
26. Topic: AS02-Epidemiology
27. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes
28. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface
29. Topic: AS02-Epidemiology
30. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib
31. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
32. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature
33. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
34. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
35. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
36. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
37. Detection of c- kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia
38. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy
39. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis
40. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
41. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis
42. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
43. A case of ‘smouldering’ mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val
44. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes
45. P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)
46. P020 Refining prognostic systems by comorbidity: are existing scores sufficient for MDS or may specific scores perform better?
47. P022 Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes
48. P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS
49. P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems
50. 12 Updated cytogenetic risk features in MDS – present state
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.